Triplet Therapeutics
Nikola Trbovic, Ph.D. is Executive Director, WRD and Principal at Pfizer Ventures. Nikola is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Arrakis, Artios, Complexa, Cydan, Jnana, Lodo, Nimbus, Palleon, and TRex.
Prior to his current role, Nikola held responsibilities for R&D technology investments, R&D strategy and early clinical portfolio management in Worldwide Research & Development at Pfizer. Nikola joined Pfizer from McKinsey Co., where he served as an Associate Principal and senior member of the Pharmaceuticals Practice, advising top pharmaceutical, biotech, and healthcare companies on a range of strategy, corporate finance and commercial topics across geographies and therapeutic areas.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.